Fig. 3.

Mono- or multisite phosphorylation of Bcl2 potently prolongs cell survival after IL-3 withdrawal or treatment with chemotherapeutic agents. (A) WT, EAA, AEA, AAE, AAA, or EEE Bcl2 mutants were stably transfected in NSF.N1/H7 cells. Expression levels of Bcl2 were determined by Western blotting by using Bcl2 antibody. (B–D) Cells expressing WT or various Bcl2 mutants were deprived of IL-3 or treated with cisplatin or paclitaxel for various times as indicated. Cell viability was determined as described for Fig. 1D. Data represent the mean ± SD of three determinations.